Hypertriglyceridemia Drugs Market Report 2026

Hypertriglyceridemia Drugs Market Overview

• Hypertriglyceridemia Drugs market size has reached to $7.06 billion in 2025 • Expected to grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: The Rise In Cardiovascular Diseases Driving The Growth Of The Hypertriglyceridemia Drugs Market Due To Unhealthy Lifestyles • Market Trend: Advancements In Ribonucleic Acid Interference-Based Triglyceride-Lowering Therapies For Severe Lipid Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hypertriglyceridemia Drugs Market?

Hypertriglyceridemia drugs refer to pharmaceutical treatments designed to reduce high triglyceride levels in the bloodstream and support overall lipid management. These medications help lower the risk of cardiovascular complications and other health conditions associated with elevated triglyceride concentrations. The main drug classes of hypertriglyceridemia drugs include statins, fibrates, omega three fatty acid derivatives, niacin, combination drugs, and other drug classes. Statins refer to lipid-lowering medications that help reduce triglyceride levels and cardiovascular risk by inhibiting cholesterol synthesis. These drugs are used for disease types including primary hypertriglyceridemia and secondary hypertriglyceridemia. They are administered through oral and injectable routes and they are utilized by end uses including hospitals, specialty clinics, and ambulatory care centers.

What Is The Hypertriglyceridemia Drugs Market Growth Forecast?

The hypertriglyceridemia drugs market size is expected to see strong growth in the next few years. It will grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing adoption of precision lipid management therapies, growth in novel biologic lipid lowering drugs, expansion of personalized medicine approaches, rising clinical trials in triglyceride targeting agents, increasing healthcare expenditure on preventive cardiometabolic care. Major trends in the forecast period include apolipoprotein C-III inhibition therapies for severe triglyceride reduction, Angiopoietin like protein 3 targeted lipid lowering drugs adoption, Microsomal triglyceride transfer protein inhibitor development for refractory hypertriglyceridemia, RNA interference based lipid metabolism regulation therapies, combination lipid lowering regimens integrating fibrates omega-3 and statins.

Global Hypertriglyceridemia Drugs Market Segmentation

1) By Drug Classes: Statins, Fibrates, Omega Three Fatty Acid Derivatives, Niacin, Combination Drugs, Other Drug Classes 2) By Disease Type: Primary Hypertriglyceridemia, Secondary Hypertriglyceridemia 3) By Route Of Administration: Oral, Injectable 4) By End Use: Hospitals, Specialty Clinics, Ambulatory Care Centers Subsegments: 1) By Statins: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin 2) By Fibrates: Fenofibrate, Gemfibrozil, Bezafibrate, Ciprofibrate 3) By Omega Three Fatty Acid Derivatives: Icosapent Ethyl, Omega Three Acid Ethyl Esters, Omega Three Carboxylic Acids, Eicosapentaenoic Acid Derivatives 4) By Niacin: Immediate Release Niacin, Extended Release Niacin, Sustained Release Niacin, Combination Niacin Formulations 5) By Combination Drugs: Statin And Fibrate Combinations, Statin And Omega Three Fatty Acid Combinations, Statin And Niacin Combinations, Multi Component Lipid Lowering Combinations 6) By Other Drug Classes: Apolipoprotein C Three Inhibitors, Angiopoietin Like Protein Three Inhibitors, Ribonucleic Acid Interference Therapies, Microsomal Triglyceride Transfer Protein Inhibitors

What Is The Driver Of The Hypertriglyceridemia Drugs Market?

The rising prevalence of cardiovascular diseases is expected to propel the growth of the hypertriglyceridemia drugs market. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, stroke, heart failure, and hypertension. The rising prevalence of cardiovascular diseases is primarily due to unhealthy lifestyles, which negatively affect heart health and increase the risk of developing heart-related disorders. Hypertriglyceridemia drugs help cardiovascular diseases by lowering excessively high triglyceride levels in the blood, thereby reducing plaque formation in arteries and decreasing the risk of heart attacks and strokes. For instance, in March 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, the number of deaths caused by cardiovascular disease (CVD) was 185 in 2023, compared to 178 recorded in 2022. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the hypertriglyceridemia drugs industry.

Key Players In The Global Hypertriglyceridemia Drugs Market

Major companies operating in the hypertriglyceridemia drugs market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, AbbVie Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Viatris Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Shionogi & Co. Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Cipla Limited, Zydus Lifesciences Limited, Kowa Company Ltd., Amarin Corporation plc, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., 89bio Inc., Arrowhead Pharmaceuticals Inc., NorthSea Therapeutics B.V., Staten Biotechnology B.V.

Global Hypertriglyceridemia Drugs Market Trends and Insights

Major companies operating in the hypertriglyceridemia drugs market are focusing on developing innovative therapies, such as ribonucleic acid interference (RNAi)-based triglyceride-lowering drugs to reduce triglyceride levels, improve cardiovascular outcomes, and address severe lipid disorders more effectively. RNAi-based triglyceride-lowering drugs are advanced therapies that use small interfering RNA molecules to selectively silence genes involved in triglyceride production and metabolism, helping reduce circulating triglyceride levels more precisely and for longer durations compared to conventional lipid-lowering medications that often require frequent dosing and may have broader systemic effects. For instance, in December 2025, Arrowhead Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for FDA Breakthrough Therapy Designation for Plozasiran, an investigational RNAi therapeutic for severe hypertriglyceridemia. The therapy is designed to reduce the production of apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism associated with elevated triglyceride levels and pancreatitis risk. Plozasiran demonstrated significant triglyceride-lowering effects in clinical studies and is intended to provide sustained efficacy with infrequent dosing schedules, improving treatment adherence and long-term lipid management. The designation highlights its potential to address unmet clinical needs among patients with severe hypertriglyceridemia who are at high risk of cardiovascular complications and acute pancreatitis.

What Are Latest Mergers And Acquisitions In The Hypertriglyceridemia Drugs Market?

In October 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, acquired 89bio Inc. for $3.5 billion. With this acquisition, Roche aims to strengthen its cardiovascular, renal, and metabolic disease portfolio by adding 89bio’s late-stage FGF21 analog therapy for metabolic dysfunction-associated steatohepatitis (MASH) and expand its presence in obesity-related and liver disease treatments. 89bio Inc. is a US-based company that is developing therapies for severe hypertriglyceridemia (SHTG), a disorder marked by extremely elevated triglyceride levels.

Regional Outlook

North America was the largest region in the hypertriglyceridemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hypertriglyceridemia Drugs Market?

The hypertriglyceridemia drugs market consists of sales of antisense oligonucleotides, peroxisome proliferator-activated receptor (PPAR) agonists, and triglyceride-lowering injectable biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hypertriglyceridemia Drugs Market Report 2026?

The hypertriglyceridemia drugs market research report is one of a series of new reports from The Business Research Company that provides hypertriglyceridemia drugs market statistics, including hypertriglyceridemia drugs industry global market size, regional shares, competitors with a hypertriglyceridemia drugs market share, detailed hypertriglyceridemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hypertriglyceridemia drugs industry. This hypertriglyceridemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.